agalsidase alfa
HGT-REP-081
Phase 3 mab completed
Quick answer
agalsidase alfa for Fabry Disease is a Phase 3 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 3 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Fabry Disease
- Phase
- Phase 3
- Modality
- mab
- Status
- completed